10x Genomics: Business Model, SWOT Analysis, and Competitors 2026

10x Genomics, Inc. stands as a leading company in Healthcare. Generating $642.82 million in annual revenue (growing 0.6% year-over-year) and carrying a market capitalization of $2.76 billion, the company has cemented its position as a foundational player in the global Health Information Services landscape. Under the leadership of its leadership team, 10x Genomics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines 10x Genomics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating 10x Genomics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define 10x Genomics, Inc.'s position in the Health Information Services market today.

What You Will Learn

1. How 10x Genomics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering 10x Genomics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who 10x Genomics, Inc.'s main competitors are and how the company compares on key financial metrics
4. 10x Genomics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. 10x Genomics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $642.82 million annual revenue (TTM), +0.6% YoY
• Market Cap: $2.76 billion — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 69.1%, operating margin -9.4%, net margin -6.8%
• Free Cash Flow: $148.39 million
• Return on Equity: -5.8% — reflects current investment phase
• Employees: 1,178 worldwide

Who Owns 10x Genomics, Inc.?

10x Genomics, Inc. is publicly traded on the NMS under the ticker symbol TXG. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of 10x Genomics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

10x Genomics, Inc. has approximately 0.12 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $21.64 per share as of early 2026.

10x Genomics, Inc.'s Mission Statement

10x Genomics, Inc.'s strategic mission is aligned with its core business activities in the Health Information Services sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — 10x Genomics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For 10x Genomics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, 10x Genomics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does 10x Genomics, Inc. Make Money?

As of 2026, 10x Genomics, Inc. generates $642.82 million in annual revenue (growing 0.6% year-over-year), with a 69.1% gross margin and -9.4% operating margin. Market capitalization stands at $2.76 billion. Here is how the company generates its revenue:

Product Sales

One of the primary sources of revenue for 10x Genomics Inc is through the sales of their products. The company offers a range of innovative solutions for genetic analysis, including their flagship product, the Chromium System. This system enables researchers to examine genomic information at single-cell resolution, allowing for a deeper understanding of biological systems.

10x Genomics Inc also offers a variety of consumables and reagents that are essential for running their systems. These products are designed to support various applications, such as single-cell gene expression profiling, immune profiling, and spatial transcriptomics. By providing these essential tools, the company generates revenue from the ongoing sales of these consumables to its customers.

Service Contracts and Support

In addition to product sales, 10x Genomics Inc also generates revenue through service contracts and support. The company offers comprehensive service plans that provide customers with access to technical support, training, and maintenance services. These contracts ensure that customers receive ongoing assistance and expertise to optimize the performance and reliability of their 10x Genomics systems.

By offering these service contracts, 10x Genomics Inc not only generates additional revenue but also fosters long-term relationships with customers. This approach helps to build customer loyalty and ensures that researchers can continue to rely on the company's products and services for their genetic analysis needs.

Collaborations and Partnerships

Another way that 10x Genomics Inc generates revenue is through collaborations and partnerships with academic institutions, research organizations, and pharmaceutical companies. Through these collaborations, the company can leverage its expertise and technologies to address specific research questions or develop novel applications in various fields.

These partnerships often involve joint research projects or co-development of new products. 10x Genomics Inc may receive funding or licensing fees from these collaborations, enabling the company to monetize its technologies and expand its product portfolio.

Intellectual Property Licensing

10x Genomics Inc holds a significant portfolio of intellectual property (IP) related to its innovative technologies and products. The company actively protects its IP through patents, trademarks, and copyrights. By licensing its IP to other companies or researcher

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review 10x Genomics, Inc.'s latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

10x Genomics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how 10x Genomics, Inc. creates, delivers, and captures value.

Key Partners: 10x Genomics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Health Information Services sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: 10x Genomics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: 10x Genomics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (1,178 employees), proprietary technology, and financial resources ($523.41M in cash).

Value Propositions: 10x Genomics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Health Information Services market.

Customer Relationships: 10x Genomics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: 10x Genomics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: 10x Genomics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: 10x Genomics, Inc.'s major costs include cost of goods sold (30.9% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 109.4% of revenue.

Revenue Streams: 10x Genomics, Inc. generates revenue through its core product and service offerings.

10x Genomics, Inc. Competitors

10x Genomics, Inc.'s main competitors include Illumina Inc, Pacific Biosciences of California Inc. The company operates in the Health Information Services segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

10x Genomics, Inc.'s competitive position in Health Information Services is defined by its $2.76B market capitalization and 69.1% gross margins. Key competitive advantages include brand recognition and operational scale in the Health Information Services market.

10x Genomics, Inc. SWOT Analysis

A SWOT analysis examines 10x Genomics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: 10x Genomics, Inc.'s gross margin of 69.1% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -9.4% demonstrates disciplined cost management even at scale.

Weaknesses

• Slowing Growth: Revenue growth of 0.6% is below what growth investors typically seek, suggesting market saturation in core businesses or increasing competitive pressure.

Opportunities

• Total Addressable Market: 10x Genomics, Inc. operates in the Health Information Services segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for 10x Genomics, Inc.'s products and services.
• Strategic Acquisitions: With $523.41M in cash and strong free cash flow generation, 10x Genomics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. 10x Genomics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on 10x Genomics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

10x Genomics, Inc. enters 2026 as a leading company in Healthcare, backed by $642.82 million in annual revenue and a -6.8% net profit margin. The company's 69.1% gross margins and $148.39 million in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in 10x Genomics, Inc.'s core markets.

For investors and analysts, 10x Genomics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – 10x Genomics, SEC EDGAR – 10x Genomics Filings, and 10x Genomics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. Is 10x Genomics a good company?

10x Genomics, Inc. generated $642.82 million in annual revenue with a -6.8% net profit margin as of the latest reporting period. The company operates in the Health Information Services sector. For the most current information, consult 10x Genomics, Inc.'s investor relations page.

2. Who are 10x Genomics competitors?

10x Genomics, Inc. competes in the Health Information Services segment of the Healthcare sector. The competitor comparison table in this article outlines key peers by market cap, revenue, and margins. Competitive dynamics in Health Information Services center on product differentiation, pricing strategy, and distribution scale.

3. What are the advantages of 10x Genomics?

10x Genomics, Inc.'s core strengths include: 10x Genomics, Inc.'s gross margin of 69.1% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -9.4% demonstrates di These advantages contribute to the company's durable competitive position in the Health Information Services sector.

4. What are the core values of 10x Genomics?

10x Genomics, Inc.'s mission and core values are disclosed in its annual report and investor relations materials. The company's stated strategic priorities — as communicated in 2025-2026 earnings calls — center on sustainable growth, operational efficiency, and shareholder returns.

5. What does 10x Genomics, Inc. do?

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enabl

6. How much revenue does 10x Genomics, Inc. make?

10x Genomics, Inc. generated $642.82 million in annual revenue (TTM), with 0.6% year-over-year growth.

7. What is 10x Genomics, Inc.'s market cap?

10x Genomics, Inc.'s market capitalization is approximately $2.76 billion as of early 2026.

8. Is 10x Genomics, Inc. profitable?

10x Genomics, Inc. has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

9. Who are 10x Genomics, Inc.'s competitors?

10x Genomics, Inc. competes in the Health Information Services sector against companies including Illumina Inc, Pacific Biosciences of California Inc.

10. Does 10x Genomics, Inc. pay dividends?

10x Genomics, Inc. does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.